+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Glioma Drug"

From
From
From
US Glioma - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

US Glioma - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • April 2023
  • 200 Pages
  • United States
From
Glioma - Competitive Landscape, 2023 - Product Thumbnail Image

Glioma - Competitive Landscape, 2023

  • Report
  • April 2023
  • 450 Pages
  • Global
From
From
Glioma - Epidemiology Forecast - 2032 - Product Thumbnail Image

Glioma - Epidemiology Forecast - 2032

  • Report
  • April 2023
  • 197 Pages
  • Global
From
From
Low-Grade Glioma - Epidemiology Forecast-2032 - Product Thumbnail Image

Low-Grade Glioma - Epidemiology Forecast-2032

  • Report
  • August 2022
  • 80 Pages
  • Global
From
High Grade Glioma - Epidemiology Forecast - 2032 - Product Thumbnail Image

High Grade Glioma - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Malignant Glioma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Malignant Glioma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Recurrent Malignant Glioma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Recurrent Malignant Glioma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
From
From
Loading Indicator

The Glioma Drug market is a subset of the larger Brain Cancer Drug market. Glioma is a type of brain cancer that is caused by the abnormal growth of glial cells in the brain. Treatment for glioma typically involves surgery, radiation therapy, chemotherapy, and targeted therapy. Drugs used to treat glioma include temozolomide, bevacizumab, and lomustine. Glioma drugs are typically used in combination with other treatments, such as radiation and surgery, to improve patient outcomes. The market for glioma drugs is expected to grow due to the increasing prevalence of brain cancer and the development of new treatments. Some companies in the Glioma Drug market include Novartis, Merck, Roche, and Pfizer. Show Less Read more